Julius Lindblom

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: RHEUMATOLOGY. 2023;62(12):3916-3923

Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State.

Hua N; Gomez A; Lindblom J; Emamikia S; Enman Y; Grannas D; Heintz E; Regardt M; Parodis I
Article: RHEUMATOLOGY. 2023;62(7):2453-2463

Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study.

Naveen R; Nikiphorou E; Joshi M; Sen P; Lindblom J; Agarwal V; Lilleker JB; Tan AL; Salim B; Ziade N; Velikova T; Gracia-Ramos AE; Kuwana M; Day J; Makol A; Distler O; Chinoy H; Traboco LS; Wibowo SAK; Tehozol EAZ; Serrano JR; García-De La Torre I; COVAD Study Group; Aggarwal R; Gupta L; Agarwal V; Parodis I
Article: RHEUMATOLOGY. 2023;62(7):2366-2376

COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis.

Naveen R; Parodis I; Joshi M; Sen P; Lindblom J; Agarwal V; Lilleker JB; Tan AL; Nune A; Shinjo SK; Salim B; Ziade N; Velikova T; Edgar Gracia-Ramos A; Saavedra MA; Day J; Makol A; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L; Nikiphorou E; COVAD Study Group
Article: JOURNAL OF AUTOIMMUNITY. 2023;136:103025

Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus.

Lindblom J; Toro-Domínguez D; Carnero-Montoro E; Beretta L; Borghi MO; Castillo J; Enman Y; PRECISESADS Clinical Consortium; Mohan C; Alarcón-Riquelme ME; Barturen G; Parodis I
Article: RHEUMATOLOGY. 2022;61(12):4752-4762

Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus.

Emamikia S; Oon S; Gomez A; Lindblom J; Borg A; Enman Y; Morand E; Grannas D; van Vollenhoven RF; Nikpour M; Parodis I
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(22):13941

B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab.

Parodis I; Gomez A; Lindblom J; Chow JW; Sjöwall C; Sciascia S; Gatto M
Article: JOURNAL OF CRANIOFACIAL SURGERY. 2022;33(2):463-468

The Volume Difference Along the External Surface of the Zygomatic Bone: A Novel Method of Measuring Zygomatic Bone Asymmetry.

Rahbin S; Toufani T; Al-Khabbaz A-M; Lindblom J; Sunnergren O; Darabi H; Qureshi AR; Alinasab B
Article: BRAIN SCIENCES. 2022;12(2):192

Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade.

Lindblom J; Mohan C; Parodis I
Article: FRONTIERS IN MEDICINE. 2022;9:1092325

EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus.

Lindblom J; Zetterberg S; Emamikia S; Borg A; von Perner G; Enman Y; Heintz E; Regardt M; Grannas D; Gomez A; Parodis I
Article: FRONTIERS IN MEDICINE. 2022;9:852162

Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus.

Parodis I; Gomez A; Lindblom J; Chow JW; Doria A; Gatto M
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:796508

Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab.

Parodis I; Gomez A; Chow JW; Borg A; Lindblom J; Gatto M
Article: RHEUMATOLOGY. 2021;60(10):4703-4716

EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus.

Lindblom J; Gomez A; Borg A; Emamikia S; Ladakis D; Matilla J; Pehr M; Cobar F; Enman Y; Heintz E; Regardt M; Parodis I
Article: RHEUMATOLOGY. 2021;60(9):4205-4217

Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE.

Borg A; Gomez A; Cederlund A; Cobar F; Qiu V; Lindblom J; Emamikia S; Enman Y; Pettersson S; Parodis I
Article: FRONTIERS IN MEDICINE. 2021;8:651249

Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus.

Gomez A; Qiu V; Cederlund A; Borg A; Lindblom J; Emamikia S; Enman Y; Lampa J; Parodis I

Alla övriga publikationer

Corrigendum: JOURNAL OF AUTOIMMUNITY. 2023;:103052

Corrigendum to 'Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus' [J. Autoimmun. 136 (April 2023) 103025].

Lindblom J; Toro-Domínguez D; Carnero-Montoro E; Beretta L; Borghi MO; Castillo J; Enman Y; PRECISESADS Clinical Consortium; Mohan C; Alarcón-Riquelme ME; Barturen G; Parodis I
Review: JOURNAL OF CLINICAL MEDICINE. 2022;11(19):5759

Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature.

Palazzo L; Lindblom J; Mohan C; Parodis I
Review: CURRENT OPINION IN RHEUMATOLOGY. 2022;34(2):139-149

Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights.

Lindblom J; Mohan C; Parodis I

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI